SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma - Quaterly Results

14 Feb 2024 Evaluate
The revenue for the December 2023 quarter is pegged at Rs. 10978.61 millions, about 18.57% up against Rs. 9258.99 millions recorded during the year-ago period.Net profit stood at Rs. 2768.05  millions  compared to Rs. 2275.36 millions in the corresponding previous quarter,high by 21.65%.The company reported a good operating profit of 4128.80 millions compared to 3454.67 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 10978.61 9258.99 18.57 29925.98 28311.06 5.70 36165.28 44007.08 -17.82
Other Income 433.90 615.09 -29.46 1197.11 2015.25 -40.60 2404.64 2239.40 7.38
PBIDT 4128.80 3454.67 19.51 10956.62 10509.21 4.26 12590.13 17345.79 -27.42
Interest 7.99 26.16 -69.46 33.09 52.33 -36.77 74.14 52.40 41.49
PBDT 4120.81 3428.51 20.19 10923.53 10456.88 4.46 11951.38 17293.39 -30.89
Depreciation 403.26 376.11 7.22 1195.44 1091.94 9.48 1467.36 1102.96 33.04
PBT 3717.55 3052.40 21.79 9728.09 9364.94 3.88 10484.02 16190.43 -35.25
TAX 949.50 777.04 22.19 2508.95 2398.74 4.59 2725.76 4068.88 -33.01
Deferred Tax 36.04 16.20 122.47 140.86 76.99 82.96 -27.99 140.08 -119.98
PAT 2768.05 2275.36 21.65 7219.14 6966.20 3.63 7758.26 12121.55 -36.00
Equity 164.70 164.69 0.01 164.70 164.69 0.01 164.70 164.30 0.24
PBIDTM(%) 37.61 37.31 0.79 36.61 37.12 -1.37 34.81 39.42 -11.68

Gland Pharma Share Price

1795.80 59.80 (3.44%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×